Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

Delayed Quote. Delayed  - 07/28 05:35:06 pm
12.255 EUR   -1.01%
07/20 ABLYNX : Announces warrant exercise
07/07 ABLYNX : 07/07/2016 ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A..
07/07 ABLYNX : ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY O..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 29TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/04/2011 | 06:10pm CEST

GHENT, Belgium, 4 January 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, 11 January 2011 at 11.00 a.m. PST / 08.00 p.m. CET.

 

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com:
http://www.ablynx.com/. A replay of the webcast will also be available on the Company's website for 30 days following the presentation.

 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

 

 

About Ablynx

Ablynx:
http://www.ablynx.com/ (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and Alzheimer's disease. Today, the Company has over 25 projects in the pipeline:
http://www.ablynx.com/en/research-development/pipeline/ and there are five Nanobodies in clinical development. In parallel with its internally developed products, Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 250 people. More information can be found on www.ablynx.com:
http://www.ablynx.com/.

 

 

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1477060/413118.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1477060


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
07/20 ABLYNX : Announces warrant exercise
07/07 ABLYNX : 07/07/2016 ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb S..
07/07 ABLYNX : ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-I..
07/04 VECTURA : Licence Option Exercised
07/01 ABLYNX : 03/06/2016 ablynx to present at the annual jefferies healthcare confere..
06/28 VECTURA : Says Partner Ablynx Exercises Commercial Licence Option
06/17 ABLYNX : 16/06/2016 correction transparency notification - adrianus van herk ann..
06/16 ABLYNX : Correction transparency notification - adrianus van herk announces 3.02..
06/16 ABLYNX : 16/06/2016 van herk investments announce 3.02% shareholding in ablynx
06/16 ABLYNX : Van herk investments announce 3.02% shareholding in ablynx
More news
Sector news : Biotechnology & Medical Research - NEC
08:46pDJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
03:28pDJU.S. HOT STOCKS : Hot Stocks to Watch
02:56pDJCELGENE : Lifts Guidance as Revlimid Sales Rise
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/07 Ablynx's vobarilizumab shows positive treatment effect in mid-stage arthritis..
05/08 Ablynx's (ABLYF) CEO Edwin Moses on Results from first-in-infant study with i..
04/12 How AbbVie Plans To Replace Humira
02/27 Ablynx's (ABLYF) CEO Edwin Moses on Q4 2015 Results - Earnings Call Transcrip..
02/25 Ablynx NV reports FY15 results
Advertisement
Financials (€)
Sales 2016 100,0 M
EBIT 2016 -8,32 M
Net income 2016 -4,75 M
Finance 2016 39,1 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 7,15x
EV / Sales 2017 16,1x
Capitalization 754 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 18,0 €
Spread / Average Target 45%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Director
Peter John Fellner Chairman
Kim Simonsen Chief Operations Officer
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX-22.23%835
INCYTE CORPORATION-18.19%16 646
CELLTRION, INC.--.--%10 582
LONZA GROUP AG11.40%9 818
QUINTILES TRANSNATIONA..9.23%8 975
ALKERMES PLC-35.74%7 827
More Results